Royal Philips Snags Additional 510(k) Clearance for Radiotherapy Simulator

Royal Philips’ magnetic resonance (MR)-only radiotherapy simulation technology has received 510(k) clearance from the FDA for use in designing pelvis cancer radiotherapy plans.

The MRCAT (magnetic resonance for calculating attenuation) technology allows clinicians to more easily create a patient’s radiotherapy treatment plan by using only a single MR exam.

The MRCAT gathers both soft tissue and density maps, allowing physicians to forego the use of computed tomography scans.